JOHANNESBURG, SOUTH AFRICA -- (Marketwire) -- 12/10/10 -- www.stockcall.com/ offers investors comprehensive research on the drug related products industry and has completed analytical research on Salix Pharmaceuticals Ltd. (NASDAQ: SLXP) and Perrigo Co. (NASDAQ: PRGO). Register with us today at www.stockcall.com/ to have free access to these researches.
Name brand and generic over the counter drug manufacturers such as Salix Pharmaceuticals Ltd. and Perrigo Co. could see revenues lowered when an aspect of healthcare reform kicks in January 1st 2011. The healthcare reform bill stipulates that over the counter drugs will no longer be a part of flexible spending plans. Investors looking for free research on Salix Pharmaceuticals Ltd. and Perrigo Co. are welcome to sign up at www.stockcall.com/SLXP101210.pdf or www.stockcall.com/PRGO101210.pdf.
www.stockcall.com/ is an online platform where investors doing their due-diligence on the drug related products industry can have easy and free access to our analyst research and opinions on Salix Pharmaceuticals Ltd. and Perrigo Co.; all investors need to do is register for a complimentary membership at https://stockcall.com/development/stockcall/page.php?name=register.html.
Flexible spending plans essentially allow an employee to set aside a specific percentage of their pay-check to be put into a healthcare expense account. The plan helps employees offset unforeseen medical expenses that they may incur throughout the year. At the moment, an employee can withdraw money from their flexible spending account to pay for over-the-counter drugs. The key component of these plans is that the money that is set aside is not subject to income, social security or Medicare taxes. Register now at https://stockcall.com/development/stockcall/page.php?name=register.html to have free access to our reports on the drug related products industry.
When the law kicks-in in January, employees will no longer be able to withdraw money from these accounts to pay for over-the-counter drugs. There are concerns that consumers will spend less because the money they personally set aside will be subject to taxes and therefore less than they would be able to spend with flexible spending accounts. Drug manufacturers are hopeful that consumers will regard the difference as negligible and maintain their spending habits. Visit www.stockcall.com/ to see how companies in this industry have grown over the past years and how they are expected to perform in the future.
Lobbying efforts are underway to reverse the reform law's position on flexible spending accounts but as it stands, it will go into effect at the beginning of the New Year. It is not yet known how much the legislative change will affect short-term revenues.
About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines.
Contact Person:
William T. Knight
stockcall2010@gmail.com